The newly launched website is designed to provide comprehensive nutritional support for individuals on their weight management journey, including those using glucagon-like peptide-1 (GLP-1) medications
GLP-1 receptor agonists produce substantial and sustained reductions in food intake clinical trials show average body weight reductions of 1322% depending on the drug, driven by smaller portions, reduced appetite for high-fat and ultra-processed foods, and a shift toward more frequent but smaller eating occasions
Anti-Inflammatory benefit of GLP-1 agonist
From reducing signs of aging to improving cholesterol levels, studies have found a long list of health benefits, from the inside out, associated with this nutrient
The FDA has specifically warned that direct-to-consumer marketing cannot imply equivalence with FDA-approved drugs - including through references to "the same active ingredient." This regulatory position applies to every compounded semaglutide program in the market, not to Novi specifically
